Literature DB >> 3422815

Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival.

A Worsley1, D G Oscier, J Stevens, S Darlow, A Figes, G J Mufti, T J Hamblin.   

Abstract

We have studied the clinical and laboratory features of 53 cases of chronic myelomonocytic leukaemia (CMML) defined according to the FAB criteria. A granulocyte count of greater than 16 X 10(9)/l or a monocyte count of greater than 2.6 X 10(9)/l correlated with a poorer survival, but the best predictor of poor survival was the modified 'Bournemouth' score in which one point each was allocated for Hb less than 10 g/dl, neutrophils less than 2.5 X 10(9)/l or greater than 16 X 10(9)/l, platelets less than 100 X 10(9)/l and bone marrow blasts greater than 5%. A score of 2 or more was predictive of poor survival (Chi2 = 10.25; P less than 0.001). Those patients with low monocyte and neutrophil counts and a low modified Bournemouth score tended to have a clinical course similar to refractory anaemia (RA) with an indolent course not requiring treatment and long survival whereas those with high monocyte and neutrophil counts and a high modified 'Bournemouth' score have a clinical course resembling that of refractory anaemia with excess of blasts (RAEB).

Entities:  

Mesh:

Year:  1988        PMID: 3422815     DOI: 10.1111/j.1365-2141.1988.tb04173.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  23 in total

1.  Long-term survivors in myelodysplastic syndromes: clinical and biological characteristics.

Authors:  Dragomir Marisavljević; Zoran Rolović; Darinka Bosković; Milica Colović
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

2.  Obstructive uropathy associated with myelomonocytic infiltration of the prostate.

Authors:  B Hope-Gill; J R Goepel; R C Collin
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

3.  Pyogenic abscesses in the myelodysplastic syndrome.

Authors:  P J Williamson; D G Oscier; G J Mufti; T J Hamblin
Journal:  BMJ       Date:  1989-08-05

Review 4.  Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.

Authors:  Dorothée Selimoglu-Buet; Eric Solary
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 5.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  [Clinical course, morphology and prognosis of chronic myelomonocytic leukemia].

Authors:  U Germing; C Strupp; G Meckenstock; A Giagounidis; H Minning; C Aul
Journal:  Med Klin (Munich)       Date:  1999-09-15

7.  Diagnosis and management of chronic myelomonocytic leukemia.

Authors:  Francesco Onida; Miloslav Beran
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

8.  Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.

Authors:  Guilin Tang; Liping Zhang; Bin Fu; Jianhua Hu; Xinyan Lu; Shimin Hu; Ankita Patel; Maitrayee Goswami; Joseph D Khoury; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

9.  Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

Authors:  Laura Palomo; Manja Meggendorfer; Stephan Hutter; Sven Twardziok; Vera Ademà; Irene Fuhrmann; Francisco Fuster-Tormo; Blanca Xicoy; Lurdes Zamora; Pamela Acha; Cassandra M Kerr; Wolfgang Kern; Jaroslaw P Maciejewski; Francesc Solé; Claudia Haferlach; Torsten Haferlach
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

10.  Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia.

Authors:  C R Bradford; S R Smith; J P Wallis
Journal:  J Clin Pathol       Date:  1993-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.